RhinoCyte
Total Raised
$4.69MInvestors Count
6Deal Terms
2Funding, Valuation & Revenue
7 Fundings
RhinoCyte has raised $4.69M over 7 rounds.
RhinoCyte's latest funding round was a Convertible Note for $0.25M on October 7, 2015.
RhinoCyte's 2014 revenue was $5M - $25M. RhinoCyte's most recent revenue is from 2014.
Sign up for a free demo to see revenue data from 2014 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/7/2015 | Convertible Note | $0.25M | Undisclosed Investors | 1 | ||
7/8/2014 | Series A - II | $5M - $25M (0.18x - 0.91x) FY 2014 | ||||
10/22/2012 | Debt - III | |||||
11/18/2011 | Debt - II | |||||
11/11/2009 | Debt |
Date | 10/7/2015 | 7/8/2014 | 10/22/2012 | 11/18/2011 | 11/11/2009 |
|---|---|---|---|---|---|
Round | Convertible Note | Series A - II | Debt - III | Debt - II | Debt |
Amount | $0.25M | ||||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | $5M - $25M (0.18x - 0.91x) FY 2014 | ||||
Sources | 1 |
RhinoCyte Deal Terms
2 Deal Terms
RhinoCyte's deal structure is available for 2 funding rounds, including their Series A - II from July 08, 2014.
Round | Series A - II | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series A - II | |||||||||||||||
Series A |
RhinoCyte Investors
6 Investors
RhinoCyte has 6 investors. Kentucky Seed Capital Fund invested in RhinoCyte's Series A - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/15/2006 | 7/8/2014 | 5 Series A, Debt (2009), Debt - II (2011), Debt - III (2012), Series A - II (2014) | Venture Capital | Kentucky | ||
Angel Investor (Group) | Ohio | |||||
Venture Capital | Ohio | |||||
Venture Capital | Kentucky | |||||
Angel Investor (Group) | Kentucky |
First funding | 8/15/2006 | ||||
|---|---|---|---|---|---|
Last Funding | 7/8/2014 | ||||
Investor | |||||
Rounds | 5 Series A, Debt (2009), Debt - II (2011), Debt - III (2012), Series A - II (2014) | ||||
Board Seats | |||||
Type | Venture Capital | Angel Investor (Group) | Venture Capital | Venture Capital | Angel Investor (Group) |
Location | Kentucky | Ohio | Ohio | Kentucky | Kentucky |
Compare RhinoCyte to Competitors
NGM Biopharmaceuticals is a biopharmaceutical company involved in the discovery and development of medicines for various diseases. The company focuses on creating biologic drug candidates to address medical needs and advancing them through clinical trials. NGM Biopharmaceuticals' research and development efforts are directed towards generating medicines that target various market indications. It was founded in 2008 and is based in South San Francisco, California.
Animal Cell Therapies specializes in the research and development of stem cell treatments within the veterinary sector. The company focuses on stem cell therapies for orthopedic and chronic diseases in companion animals. These treatments aim to address acute and chronic conditions. It is based in San Diego, California.
BioRegenix is a biotechnology company committed to the development of tissue regeneration technology.
Cell Line Genetics provides services for the regenerative medicine sector, including cell line authentication, genetic integrity assessments, and cytogenetic analysis tools. The company serves universities, research institutes, and the biotechnology and pharmaceutical industries. It is based in Madison, Wisconsin.
Enzo Biochem specializes in product development within the biomedical research and healthcare sectors. The company offers a range of products, such as antibodies, genomic probes, assays, biochemicals, and proteins, that support academic research centers and industry partners in healthcare. Enzo Biochem's technologies are used in various aspects of translational research and drug development, including genomic, protein, cellular, tissue analysis, and small molecule chemistry. It was founded in 1976 and is based in Farmingdale, New York.
Minerva Biotechnologies is a clinical stage biopharmaceutical company involved in the development of immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. The company creates CAR T cell therapies that target the MUC1* growth factor receptor to treat solid tumors and is developing CAR-T products and other therapeutic modalities aimed at cancer metastasis. Additionally, Minerva is researching stem cell technologies for regenerative medicine. It was founded in 1999 and is based in Waltham, Massachusetts.
Loading...